Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group
J Dermatolog Treat. 2022 May 26:1-3. doi: 10.1080/09546634.2022.2079596. Online ahead of print.
NO ABSTRACT
PMID:35593480 | DOI:10.1080/09546634.2022.2079596
Von Automat